Phillip Barnette

1.7k total citations
26 papers, 672 citations indexed

About

Phillip Barnette is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Oncology. According to data from OpenAlex, Phillip Barnette has authored 26 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Public Health, Environmental and Occupational Health, 9 papers in Hematology and 8 papers in Oncology. Recurrent topics in Phillip Barnette's work include Acute Lymphoblastic Leukemia research (16 papers), Acute Myeloid Leukemia Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Phillip Barnette is often cited by papers focused on Acute Lymphoblastic Leukemia research (16 papers), Acute Myeloid Leukemia Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Phillip Barnette collaborates with scholars based in United States, Germany and Canada. Phillip Barnette's co-authors include Mignon L. Loh, Bruce Bostrom, Elena Eckroth, Nita L. Seibel, Elizabeth A. Raetz, Clare J. Twist, Raymond J. Hutchinson, Richard H. Ko, Paul S. Gaynon and Lingyun Ji and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Phillip Barnette

25 papers receiving 663 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Phillip Barnette United States	11	255	254	189	178	146	26	672
Gabriel Rivera United States	9	182 0.7×	163 0.6×	122 0.6×	121 0.7×	156 1.1×	16	570
CM Niemeyer United States	9	114 0.4×	248 1.0×	151 0.8×	346 1.9×	44 0.3×	15	631
Yacov Goshen Israel	13	88 0.3×	74 0.3×	162 0.9×	56 0.3×	127 0.9×	18	443
Keiichi Isoyama Japan	15	99 0.4×	289 1.1×	187 1.0×	400 2.2×	46 0.3×	50	705
Pearl Leavitt United States	10	255 1.0×	534 2.1×	268 1.4×	561 3.2×	50 0.3×	13	1.1k
Kang Howson‐Jan Canada	12	203 0.8×	56 0.2×	137 0.7×	404 2.3×	67 0.5×	33	666
R T Silver United States	14	158 0.6×	128 0.5×	49 0.3×	345 1.9×	87 0.6×	24	620
Samuel Kopel United States	8	197 0.8×	179 0.7×	155 0.8×	369 2.1×	59 0.4×	14	628
Kwai Han Yoo South Korea	15	270 1.1×	31 0.1×	183 1.0×	85 0.5×	210 1.4×	50	588
Atsuo Okamura Japan	14	187 0.7×	38 0.1×	142 0.8×	172 1.0×	79 0.5×	61	577

Countries citing papers authored by Phillip Barnette

Since Specialization

Citations

This map shows the geographic impact of Phillip Barnette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip Barnette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip Barnette more than expected).

Fields of papers citing papers by Phillip Barnette

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip Barnette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip Barnette. The network helps show where Phillip Barnette may publish in the future.

Co-authorship network of co-authors of Phillip Barnette

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip Barnette. A scholar is included among the top collaborators of Phillip Barnette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip Barnette. Phillip Barnette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barnette, Phillip, et al.. (2020). Cost savings of biosimilars in oncology: A single institution experience.. Journal of Clinical Oncology. 38(29_suppl). 10–10. 2 indexed citations

Verma, Anupam, et al.. (2019). PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability. Pediatric Hematology and Oncology. 36(5). 277–286. 21 indexed citations

Verma, Anupam, Karin Chen, Jacob Johnsen, & Phillip Barnette. (2018). Pegylated E. coli Asparaginase Desensitization: An Effective and Feasible Option for Pediatric Patients with Acute Lymphoblastic Leukemia Who Have Developed Hypersensitivity to Pegaspargase in the Absence of Asparaginase Erwinia Chrysanthemi availability. Blood. 132(Supplement 1). 5205–5205. 2 indexed citations

Vo, Kieuhoa T., C. Lorrie Epling, Elizabeth Sinclair, et al.. (2016). Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research. 22(14). 3643–3650. 17 indexed citations

Meyer, Julia A., Delu Zhou, Clinton C. Mason, et al.. (2016). Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatric Blood & Cancer. 64(7). e26363–e26363. 10 indexed citations

Handgretinger, Rupert, Lia Gore, Gerhard Zugmaier, et al.. (2015). Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Following Blinatumomab-Induced Remission in Pediatric Patients with Relapsed/Refractory (r/r) B-Precursor Acute Lymphoblastic Leukemia (ALL): Preliminary Results from a Phase I/II Stud. Biology of Blood and Marrow Transplantation. 21(2). S186–S187.

Topp, Max S., Matthias Stelljes, Gerhard Zugmaier, et al.. (2015). Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL).. Journal of Clinical Oncology. 33(15_suppl). 7051–7051. 6 indexed citations

Gore, Lia, Franco Locatelli, Gerhard Zugmaier, et al.. (2014). Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood. 124(21). 3703–3703. 19 indexed citations

Gore, Lia, Margaret E. Macy, Françoise Méchinaud, et al.. (2012). Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML). Blood. 120(21). 1517–1517. 2 indexed citations

10.

Leventaki, Vasiliki, Sheryl R. Tripp, Michael G. Bayerl, et al.. (2012). TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. British Journal of Haematology. 158(6). 763–771. 19 indexed citations

11.

Schiffman, Joshua D., Mona S. Jahromi, Jonathan M. Downie, et al.. (2011). Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin‐fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. British Journal of Haematology. 155(4). 477–486. 45 indexed citations

12.

Alaggio, Rita, Paola Collini, R. Lor Randall, et al.. (2010). Undifferentiated High-Grade Pleomorphic Sarcomas in Children: A Clinicopathologic Study of 10 Cases and Review of Literature. Pediatric and Developmental Pathology. 13(3). 209–217. 15 indexed citations

13.

Gorman, Matthew F., Lingyun Ji, Richard H. Ko, et al.. (2010). Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study. Pediatric Blood & Cancer. 55(3). 421–429. 83 indexed citations

14.

Downie, Jonathan M., Phillip Barnette, J. Kimble Frazer, et al.. (2010). T-Cell Receptor Gene Deletions Are Associated with High Risk Features and Worse Outcome In Childhood Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood. 116(21). 275–275. 1 indexed citations

15.

Tap, William D., G. D. Demetri, Phillip Barnette, et al.. (2010). AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results.. Journal of Clinical Oncology. 28(15_suppl). 10001–10001. 18 indexed citations

16.

Ko, Richard H., Lingyun Ji, Phillip Barnette, et al.. (2009). Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study. Journal of Clinical Oncology. 28(4). 648–654. 191 indexed citations

17.

Downie, Jonathan M., et al.. (2009). Novel Use of Molecular Inversion Probes to Interrogate Formalin-Fixed Paraffin-Embedded (FFPE) Samples of Childhood Leukemia.. Blood. 114(22). 1589–1589. 1 indexed citations

18.

Tward, Jonathan D., Martha Glenn, Michael A. Pulsipher, Phillip Barnette, & David K. Gaffney. (2007). Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leukemia & lymphoma. 48(8). 1482–1495. 6 indexed citations

19.

Wagner, Lars M., Sylvie M. Guichard, Susana C. Raimondi, et al.. (2006). Pilot Study to Evaluate MYCN Expression as a Neuroblastoma Cell Marker to Detect Minimal Residual Disease by RT-PCR. Journal of Pediatric Hematology/Oncology. 28(10). 635–641. 1 indexed citations

20.

Barnette, Phillip, L. Ballard, Alexander Tsodikov, et al.. (2004). High-Throughput Detection of Glutathione S -Transferase Polymorphic Alleles in a Pediatric Cancer Population. Cancer Epidemiology Biomarkers & Prevention. 13(2). 304–313. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact